Chugai Pharmaceutical (OTCMKTS:CHGCY) Sets New 12-Month High – What’s Next?

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) shares reached a new 52-week high during mid-day trading on Friday . The stock traded as high as $33.23 and last traded at $31.8550, with a volume of 240600 shares changing hands. The stock had previously closed at $30.75.

Analyst Upgrades and Downgrades

Separately, UBS Group upgraded Chugai Pharmaceutical to a “strong-buy” rating in a report on Tuesday, January 27th. One equities research analyst has rated the stock with a Strong Buy rating, Based on data from MarketBeat.com, the company has an average rating of “Strong Buy”.

Chugai Pharmaceutical Trading Up 4.1%

The firm has a market cap of $105.35 billion, a price-to-earnings ratio of 36.79 and a beta of 0.63. The stock’s fifty day moving average price is $27.54 and its 200-day moving average price is $24.97.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last issued its quarterly earnings data on Thursday, January 29th. The company reported $0.25 earnings per share (EPS) for the quarter. Chugai Pharmaceutical had a net margin of 34.47% and a return on equity of 22.00%. The firm had revenue of $2.25 billion for the quarter. Analysts predict that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.74 earnings per share for the current year.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co, Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai’s activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support.

Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics.